Kyowa Kirin Co., Ltd.
4151
Peringkat dalam Saham
#2450
Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused... Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused on the discovery, development, manufacturing, and marketing of innovative medical therapies. The company's core areas of expertise span oncology, nephrology, central nervous system disorders, and immunology. Its extensive product portfolio includes established medications such as ABSTRAL, a sublingual fentanyl formulation for managing breakthrough pain in cancer patients; ALLELOCK, an antihistamine for various allergic conditions; and CONIEL, a calcium channel blocker prescribed for hypertension and angina. Kyowa Kirin also provides a range of advanced biological and specialized treatments. These encompass Crysvita, a recombinant human monoclonal IgG1 antibody targeting fibroblast growth factor 23, and blood-related therapies like ESPO (human erythropoietin), NESP (an erythropoiesis stimulating agent), and GRAN (a human colony-stimulating factor). Further products in its lineup address diverse medical needs: G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for opioid-induced constipation; Nouriast/Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. Other significant offerings are PecFent, a nasally administered spray; POTELIGEO, a humanized monoclonal antibody targeting CC chemokine receptor 4; REGPARA for secondary hyperparathyroidism; Romiplate/Nplate, a recombinant protein promoting platelet production; and SANCUSO for managing nausea and vomiting. Beyond its current offerings, Kyowa Kirin is actively involved in pipeline development, notably through a strategic collaboration with Amgen Inc. for the joint development and commercialization of KHK4083. This Phase 3-ready, fully human anti-OX40 monoclonal antibody is being developed to treat atopic dermatitis. Established in Tokyo, Japan, in 1949, the company changed its name from Kyowa Hakko Kirin Co., Ltd. to Kyowa Kirin Co., Ltd. in June 2019. It operates as a subsidiary of Kirin Holdings Company, Limited.
Harga Saham
$15.23
Kapitalisasi Pasar
$7.98B
Perubahan (1 hari)
-0.30%
Perubahan (1 tahun)
2.82%
Negara
JP
Perdagangan Kyowa Kirin Co., Ltd. (4151)
Kategori
Healthcare
Margin Operasi untuk Kyowa Kirin Co., Ltd. (4151)
Margin Operasi per October 2026 TTM: 24.38%
Menurut laporan keuangan dan harga saham terbaru dari Kyowa Kirin Co., Ltd., margin operasi saat ini (TTM) adalah 24.38%. Pada akhir 2024, margin operasi perusahaan adalah 18.54%.
Riwayat margin operasi untuk Kyowa Kirin Co., Ltd. dari 2001 hingga 2026
Margin Operasi pada akhir setiap tahun
| Tahun | Margin Operasi | Mengubah |
|---|---|---|
| 2026 (TTM) | 24.38% | 18.41% |
| 2025 | 20.59% | 11.06% |
| 2024 | 18.54% | -14.44% |
| 2023 | 21.67% | 4.79% |
| 2022 | 20.68% | 19.12% |
| 2021 | 17.36% | -6.31% |
| 2020 | 18.53% | 23.70% |
| 2019 | 14.98% | -30.81% |
| 2018 | 21.65% | 32.50% |
| 2017 | 16.34% | 77.22% |
| 2016 | 9.22% | -23.23% |
| 2015 | 12.01% | 10.69% |
| 2014 | 10.85% | -28.62% |
| 2013 | 15.20% | -4.28% |
| 2012 | 15.88% | -35.84% |
| 2011 | 24.75% | 125.41% |
| 2010 | 10.98% | 20.13% |
| 2009 | 9.14% | -9.05% |
| 2008 | 10.05% | 18.10% |
| 2007 | 8.51% | 17.87% |
| 2006 | 7.22% | -22.62% |
| 2005 | 9.33% | 21.33% |
| 2004 | 7.69% | 47.04% |
| 2003 | 5.23% | -2.79% |
| 2002 | 5.38% | 13.98% |
| 2001 | 4.72% | 0.00% |
Margin Operasi untuk perusahaan sejenis atau pesaing
| Perusahaan | Margin Operasi | Perbedaan Margin Operasi | Negara |
|---|---|---|---|
| 49.72% | -97.96% |
US
|
|
| 25.70% | -98.95% |
US
|
|
| 29.32% | -98.80% |
US
|
|
| 26.59% | -98.91% |
CH
|
|
| 16.65% | -99.32% |
US
|
Apa itu Margin Operasi perusahaan?
Margin Operasi adalah indikator utama untuk menilai profitabilitas suatu perusahaan. Margin Operasi yang lebih tinggi umumnya lebih baik karena menunjukkan bahwa perusahaan mampu menjual produk atau layanan mereka dengan harga yang jauh lebih tinggi daripada biaya produksinya. Margin Operasi dihitung dengan membagi laba perusahaan dengan pendapatannya.